Literature DB >> 1972009

Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA.

K P Yang1, C V Nguyen, S G Castillo, N A Samaan.   

Abstract

Multiple endocrine neoplasia type IIA (MEN IIA) syndrome is an autosomal-dominant endocrine disorder that consists of medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid hyperplasia. The susceptibility gene to this disorder has been mapped to chromosome 10. However, molecular studies of tumor cells from patients with familial and sporadic MTC and/or pheochromocytoma have shown a high frequency (50%) of abnormalities on chromosome 1p. In the present study, we examined MTC or pheochromocytoma tumor specimens from eight patients (familial and nonfamilial cases) to investigate gene losses on chromosomes 1 and 10 as potential mechanisms for the tumors' development. The patients studies had homozygous genotypes in their leukocyte DNAs for the chromosome 10 marker used in this study, and the patients were, therefore, uninformative. However, the patients were informative for the chromosome 1 markers and five of the patients' tumor-cell DNAs (63%) had allelic deletions at one or multiple loci on chromosome 1p, and one tumor DNA had evidence of possible gene rearrangement; in all six cases, the abnormalities involved the distal third of chromosome 1p. Furthermore, we determined that the common break point for the 1p deletions was at 1p32. These results suggest that a tumor suppressor gene in this defined region is involved in the development/progression of MTC and pheochromocytoma by being either lost or inactivated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972009

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

Authors:  H Dannenberg; E J Speel; J Zhao; P Saremaslani; E van Der Harst; J Roth; P U Heitz; H J Bonjer; W N Dinjens; W J Mooi; P Komminoth; R R de Krijger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.

Authors:  S Khosla; V M Patel; I D Hay; D J Schaid; C S Grant; J A van Heerden; S N Thibodeau
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

Review 3.  Biology of tumors of the peripheral nervous system.

Authors:  G M Brodeur; J F Moley
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

4.  Chromosome mapping of the human cytidine-5'-triphosphate synthetase (CTPS) gene to band 1p34.1-p34.3 by fluorescence in situ hybridization.

Authors:  E Takahashi; M Yamauchi; H Tsuji; A Hitomi; M Meuth; T Hori
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

Review 5.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Authors:  Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

7.  Chromosome 1 in human colorectal tumors. Cytogenetic research on structural changes and their significance.

Authors:  M H Couturier-Turpin; C Esnous; A Louvel; Y Poirier; D Couturier
Journal:  Hum Genet       Date:  1992-02       Impact factor: 4.132

8.  Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma.

Authors:  K Kubo; K Yoshimoto; Y Yokogoshi; M Tsuyuguchi; S Saito
Journal:  Jpn J Cancer Res       Date:  1991-10

9.  Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

Authors:  I Yana; T Nakamura; E Shin; K Karakawa; H Kurahashi; Y Kurita; T Kobayashi; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-11

10.  Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.

Authors:  S Uchino; S Noguchi; M Adachi; M Sato; H Yamashita; S Watanabe; T Murakami; M Toda; N Murakami; H Yamashita
Journal:  Jpn J Cancer Res       Date:  1998-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.